Fibrinogen is not a prognostic factor for response to HELP-apheresis in sudden sensorineural hearing loss (SSHL)
- PMID: 25527412
- DOI: 10.1007/s00405-014-3449-9
Fibrinogen is not a prognostic factor for response to HELP-apheresis in sudden sensorineural hearing loss (SSHL)
Abstract
Higher levels of fibrinogen or cholesterol were associated with improved hearing recovery in SSHL patients after treatment with HELP-apheresis (Heparin-induced extracorporeal LDL precipitation apheresis). The present trial was performed to demonstrate HELP-related effects on relevant metabolic and inflammatory parameters in the context of SSHL treatment. In the framework of a single arm non-controlled trial, we investigated the variation of metabolic and inflammatory parameters using HELP-apheresis for a defined group of 100 patients with SSHL. Based on cut off inclusion criteria (Serum LDL-cholesterol >1.6 g/l and/or fibrinogen >2.0 g/l, SSHL in minimum three frequencies more than 30 dB, time after event not longer than 6 days), the protocol followed a strict time line with one single shot HELP-apheresis and follow-up monitoring including laboratory parameters at six defined time points. If HELP-apheresis could not effect improvement of hearing on day 5, additional corticosteroid treatment was applied. Concentration of anti-inflammatory IL-10 increased while other proinflammatory parameters declined. Serum levels of all measured sterols and apolipoproteins decreased significantly. None of the investigated parameters were suitable to predict hearing improvement of the patients. Levels of fibrinogen and LDL-cholesterol were not prognostic for outcome after HELP-apheresis. A significant (p < 0.001) increase of anti-inflammatory IL-10 after apheresis was notable, while most of the proinflammatory parameters declined. Despite the limited validity of a single arm non-controlled trial, these alterations on immune modulating factors indicate possible secondary pleiotropic effects caused by HELP-apheresis.
Keywords: Fibrinogen; HELP-apheresis; Inflammatory parameters; LDL-Cholesterol; Sudden sensorineural hearing loss.
Similar articles
-
[Treatment of sudden hearing loss through Fibrinogen/LDL-apheresis. A prospective, randomized multicenter trial].Z Kardiol. 2003;92(Suppl 3):III59-63. doi: 10.1007/s00392-003-1309-5. Z Kardiol. 2003. PMID: 14663604 Clinical Trial. German.
-
[Treatment of sudden sensorineural hearing loss (SSHL) with HELP-apheresis: our experience].G Ital Nefrol. 2012 Jan-Feb;29 Suppl 54:S138-40. G Ital Nefrol. 2012. PMID: 22388846 Italian.
-
Treatment with HELP-apheresis in patients suffering from sudden sensorineural hearing loss: a prospective, randomized, controlled study.Laryngoscope. 2010 Apr;120(4):800-7. doi: 10.1002/lary.20835. Laryngoscope. 2010. PMID: 20213795 Clinical Trial.
-
The Role of Fibrinogen, Homocysteine and Metabolic Syndrome's Alterations in Sudden Sensorineural Hearing Loss (SSHL): A Narrative Review.Medicina (Kaunas). 2023 Nov 9;59(11):1977. doi: 10.3390/medicina59111977. Medicina (Kaunas). 2023. PMID: 38004026 Free PMC article. Review.
-
[Heparin-induced extracorporeal LDL precipitation (H.E.L.P.)].Z Kardiol. 2003;92(Suppl 3):III1-5. doi: 10.1007/s00392-003-1304-x. Z Kardiol. 2003. PMID: 14663596 Review. German.
Cited by
-
Current Role of the Nonsteroid Treatment of Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL): A Narrative Review.J Clin Med. 2025 Apr 18;14(8):2811. doi: 10.3390/jcm14082811. J Clin Med. 2025. PMID: 40283640 Free PMC article. Review.
-
Efficacy and fibrinogen correlations of defibrinogen therapy in idiopathic sudden sensorineural hearing loss.Sci Rep. 2025 Feb 5;15(1):4311. doi: 10.1038/s41598-024-84723-3. Sci Rep. 2025. PMID: 39910104 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous